{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T13:59:57Z","timestamp":1793973597021,"version":"4.8.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T00:00:00Z","timestamp":1730937600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jhep-reports.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JHEP Reports"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.jhepr.2024.101268","type":"journal-article","created":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T20:33:53Z","timestamp":1731443633000},"page":"101268","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Lower incidence of hepatocellular carcinoma with tenofovir alafenamide in chronic hepatitis B: Evidence from a large-scale cohort"],"prefix":"10.1016","volume":"7","author":[{"given":"Hye-Jin","family":"Yoo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae-Young","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7802-0381","authenticated-orcid":false,"given":"Jeong-Ju","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3552-3560","authenticated-orcid":false,"given":"Hye Won","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Gyune","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7113-3623","authenticated-orcid":false,"given":"Young Seok","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhepr.2024.101268_bib1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.jhepr.2024.101268_bib2","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1016\/j.jhep.2022.08.021","article-title":"Global burden of primary liver cancer in 2020 and predictions to 2040","volume":"77","author":"Rumgay","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2024.101268_bib3","first-page":"62","article-title":"Changing etiology and epidemiology of hepatocellular carcinoma: Asia and worldwide","volume":"24","author":"Kim","year":"2024","journal-title":"J\u00a0Liver Cancer"},{"key":"10.1016\/j.jhepr.2024.101268_bib4","first-page":"1","article-title":"2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma","volume":"23","year":"2023","journal-title":"J\u00a0Liver Cancer"},{"key":"10.1016\/j.jhepr.2024.101268_bib5","doi-asserted-by":"crossref","first-page":"e89","DOI":"10.3346\/jkms.2021.36.e89","article-title":"Entecavir versus tenofovir for the prevention of hepatocellular carcinoma in treatment-naive chronic hepatitis B patients in Korea","volume":"36","author":"Choi","year":"2021","journal-title":"J\u00a0Korean Med Sci"},{"key":"10.1016\/j.jhepr.2024.101268_bib6","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1001\/jamaoncol.2018.4070","article-title":"Risk of hepatocellular carcinoma in patients treated with entecavir vs tenofovir for chronic hepatitis B: a Korean nationwide cohort study","volume":"5","author":"Choi","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jhepr.2024.101268_bib7","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.19407","article-title":"Risk of hepatocellular carcinoma with tenofovir vs entecavir treatment for chronic hepatitis B virus: a reconstructed individual patient data meta-analysis","volume":"5","author":"Tan","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jhepr.2024.101268_bib8","doi-asserted-by":"crossref","DOI":"10.14309\/ctg.0000000000000236","article-title":"Entecavir vs tenofovir in hepatocellular carcinoma prevention in chronic hepatitis B infection: a systematic review and meta-analysis","volume":"11","author":"Cheung","year":"2020","journal-title":"Clin Transl Gastroenterol"},{"key":"10.1016\/j.jhepr.2024.101268_bib9","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/j.cgh.2022.02.056","article-title":"The risk of hepatocellular carcinoma in entecavir versus tenofovir treated US cohort with chronic hepatitis B virus","volume":"21","author":"Kramer","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2024.101268_bib10","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.jhep.2022.12.007","article-title":"Hepatocellular carcinoma risk in patients with chronic hepatitis B receiving tenofovir- vs. entecavir-based regimens: individual patient data meta-analysis","volume":"78","author":"Choi","year":"2023","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2024.101268_bib11","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.cgh.2020.05.008","article-title":"Effects of tenofovir vs entecavir on risk of hepatocellular carcinoma in patients with chronic HBV infection: a systematic review and meta-analysis","volume":"19","author":"Choi","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2024.101268_bib12","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/S2468-1253(20)30249-1","article-title":"Hepatocellular carcinoma incidence with tenofovir versus entecavir in chronic hepatitis B: a systematic review and meta-analysis","volume":"5","author":"Tseng","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2024.101268_bib13","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1111\/jgh.15036","article-title":"Comparison of tenofovir versus entecavir on reducing incidence of hepatocellular carcinoma in chronic hepatitis B patients: a systematic review and meta-analysis","volume":"35","author":"Gu","year":"2020","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2024.101268_bib14","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1136\/gutjnl-2019-318947","article-title":"Comparison of tenofovir and entecavir on the risk of hepatocellular carcinoma and mortality in treatment-naive patients with chronic hepatitis B in Korea: a large-scale, propensity score analysis","volume":"69","author":"Lee","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.jhepr.2024.101268_bib15","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1111\/apt.16788","article-title":"Review article: switching patients with chronic hepatitis B to tenofovir alafenamide-a review of current data","volume":"55","author":"Lim","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhepr.2024.101268_bib16","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/jgh3.12481","article-title":"Bone and renal safety profile at 72 weeks after switching to tenofovir alafenamide in chronic hepatitis B patients","volume":"5","author":"Lee","year":"2021","journal-title":"JGH Open"},{"key":"10.1016\/j.jhepr.2024.101268_bib17","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-013752","article-title":"Liver cirrhosis in England-an observational study: are we measuring its burden occurrence correctly?","volume":"7","author":"Ratib","year":"2017","journal-title":"BMJ Open"},{"key":"10.1016\/j.jhepr.2024.101268_bib18","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgast-2020-000485","article-title":"ICD-10-AM codes for cirrhosis and related complications: key performance considerations for population and healthcare studies","volume":"7","author":"Hayward","year":"2020","journal-title":"BMJ Open Gastroenterol"},{"key":"10.1016\/j.jhepr.2024.101268_bib19","doi-asserted-by":"crossref","first-page":"e22","DOI":"10.3346\/jkms.2024.39.e22","article-title":"The epidemiology of hepatitis B virus infection in Korea: 15-year analysis","volume":"39","author":"Kim","year":"2024","journal-title":"J\u00a0Korean Med Sci"},{"key":"10.1016\/j.jhepr.2024.101268_bib20","doi-asserted-by":"crossref","first-page":"283","DOI":"10.3350\/cmh.2020.0227","article-title":"Association between new-onset liver cirrhosis and suicide risk in South Korea: a nationwide cohort study","volume":"27","author":"Jang","year":"2021","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.jhepr.2024.101268_bib21","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1007\/s12072-021-10234-2","article-title":"Impact of tenofovir alafenamide vs. entecavir on hepatocellular carcinoma risk in patients with chronic hepatitis B","volume":"15","author":"Lee","year":"2021","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhepr.2024.101268_bib22","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1007\/s12072-021-10262-y","article-title":"Efficacy of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide in treatment-naive hepatitis B patients","volume":"15","author":"Chon","year":"2021","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhepr.2024.101268_bib23","article-title":"Tenofovir alafenamide and tenofovir disoproxil fumarate reduce incidence of hepatocellular carcinoma in patients with chronic hepatitis B","volume":"5","author":"Lim","year":"2023","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhepr.2024.101268_bib24","doi-asserted-by":"crossref","first-page":"5917","DOI":"10.1128\/AAC.01151-15","article-title":"Characterization of HIV-1 resistance to tenofovir alafenamide in\u00a0vitro","volume":"59","author":"Margot","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhepr.2024.101268_bib25","article-title":"A\u00a0review and clinical understanding of tenofovir: tenofovir disoproxil fumarate versus tenofovir alafenamide","volume":"19","author":"Wassner","year":"2020","journal-title":"J\u00a0Int Assoc Provid AIDS Care"},{"key":"10.1016\/j.jhepr.2024.101268_bib26","doi-asserted-by":"crossref","DOI":"10.1177\/1756284818786108","article-title":"Tenofovir alafenamide in the treatment of chronic hepatitis B virus infection: rationale and clinical trial evidence","volume":"11","author":"Byrne","year":"2018","journal-title":"Thera Adv Gastroenterol"},{"key":"10.1016\/j.jhepr.2024.101268_bib27","doi-asserted-by":"crossref","first-page":"9427","DOI":"10.3748\/wjg.v20.i28.9427","article-title":"Osteoporosis and fractures in liver disease: relevance, pathogenesis and therapeutic implications","volume":"20","author":"Nakchbandi","year":"2014","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jhepr.2024.101268_bib28","doi-asserted-by":"crossref","first-page":"4270","DOI":"10.3390\/ijms20174270","article-title":"Bone diseases in patients with chronic liver disease","volume":"20","author":"Jeong","year":"2019","journal-title":"Int J Mol Sci"}],"container-title":["JHEP Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555924002726?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555924002726?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,2]],"date-time":"2025-03-02T00:58:26Z","timestamp":1740877106000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589555924002726"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S2589555924002726"],"URL":"https:\/\/doi.org\/10.1016\/j.jhepr.2024.101268","relation":{},"ISSN":["2589-5559"],"issn-type":[{"value":"2589-5559","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lower incidence of hepatocellular carcinoma with tenofovir alafenamide in chronic hepatitis B: Evidence from a large-scale cohort","name":"articletitle","label":"Article Title"},{"value":"JHEP Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhepr.2024.101268","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).","name":"copyright","label":"Copyright"}],"article-number":"101268"}}